Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics
Akebia Therapeutics, Inc. (AKBA)
Today's Latest Price: $10.98 USD
Updated Aug 7 12:00am
Add AKBA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AKBA Stock Summary
- Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 17.51% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 226.73%, Akebia Therapeutics Inc's debt growth rate surpasses 93.4% of about US stocks.
- Revenue growth over the past 12 months for Akebia Therapeutics Inc comes in at 49.61%, a number that bests 89.7% of the US stocks we're tracking.
- Stocks that are quantitatively similar to AKBA, based on their financial statements, market capitalization, and price volatility, are ONTX, INFI, ADXS, IPHA, and VNE.
- AKBA's SEC filings can be seen here. And to visit Akebia Therapeutics Inc's official web site, go to www.akebia.com.
AKBA Stock Price Chart Technical Analysis Charts
AKBA Price/Volume Stats
| Current price | $10.98 | 52-week high | $13.71 |
| Prev. close | $11.06 | 52-week low | $2.99 |
| Day low | $10.93 | Volume | 920,900 |
| Day high | $11.57 | Avg. volume | 1,537,712 |
| 50-day MA | $12.04 | Dividend yield | N/A |
| 200-day MA | $8.49 | Market Cap | 1.43B |
Akebia Therapeutics, Inc. (AKBA) Company Bio
Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Loading social stream, please wait...